Open AccessRegional variation in tolvaptan prescribing across England: national data and retrospective evaluation from an expert centre
Author(s) -
Jiehan Chong,
Tess Harris,
Albert Ong
Publication year - 2022
Publication title -
clinical kidney journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 40
eISSN - 2048-8513
pISSN - 2048-8505
DOI - 10.1093/ckj/sfac190
Subject(s) - tolvaptan , medicine , autosomal dominant polycystic kidney disease , retrospective cohort study , renal function , discontinuation , cohort , kidney disease , family medicine , disease , vasopressin
Tolvaptan, a vasopressin V2 receptor antagonist, was approved in 2015 by the UK National Institute for Health and Care Excellence for use in patients with autosomal dominant polycystic kidney disease (ADPKD) and rapid disease progression. Simultaneous guidance was issued by the UK Kidney Association (UKKA) to facilitate national implementation.